

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM805838

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	MERGER		
EFFECTIVE DATE:	03/31/2023		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Medtor, Inc.		03/30/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	BioIntelliSense, Inc.		
Street Address:	17301 W. Colfax Avenue, Suite 152		
City:	Golden		
State/Country:	COLORADO		
Postal Code:	80401		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Serial Number:	90634401	SAFESAT SENTRY	
Serial Number:	90579081	SAFESAT MONARCH	
Registration Number:	5105318	SAFESAT	
Serial Number:	88944113	MONARCH	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	wsavoy@patentgc.com		
Correspondent Name:	Wade Savoy		
Address Line 1:	Patent GC LLC		
Address Line 2:	501 Boylston Street, 10th Floor		
Address Line 4:	Boston, MASSACHUSETTS 02116		
ATTORNEY DOCKET NUMBER:	BioIntelliSense		
NAME OF SUBMITTER:	Wade Savoy		
SIGNATURE:	/Wade J. Savoy/		
DATE SIGNED:	04/25/2023		
Total Attachments: 4			

OP \$115.00 90634401

source=Medtor Merger#page1.tif
source=Medtor Merger#page2.tif
source=Medtor Merger#page3.tif
source=Medtor Merger#page4.tif

Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"MEDTOR, INC.", A DELAWARE CORPORATION,

WITH AND INTO "BIOINTELLISENSE, INC." UNDER THE NAME OF "BIOINTELLISENSE, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE THIRTIETH DAY OF MARCH, A.D. 2023, AT 2:34 O`CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF OWNERSHIP IS THE THIRTY-FIRST DAY OF MARCH, A.D. 2023.




Jeffrey W. Bullock, Secretary of State

6898579 8100M
SR# 20231226672

You may verify this certificate online at corp.delaware.gov/authver.shtml

Authentication: 203058581
Date: 04-03-23

TRADEMARK
REEL: 008052 FRAME: 0043

STATE of DELAWARE

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

MEDTOR, INC.
a Delaware corporation

WITH AND INTO

BIOINTELLISENSE, INC.
a Delaware corporation

*Pursuant to Title 8, Chapter 18, Section 253
of the Delaware Code*

BioIntelliSense, Inc. ("Parent" or "Corporation"), a corporation organized and existing under the laws of the State of Delaware,

DOES HEREBY CERTIFY:

FIRST: Parent was organized on the 23rd day of May, 2018 pursuant to the Delaware General Corporation Law (the "DGCL"), the provisions of which permit the merger of a subsidiary corporation into a parent corporation.

SECOND: That Parent owns 100% of the outstanding shares of the capital stock of Medtor, Inc. ("Merger Sub"), a corporation organized on the 10th day of September, 2002, pursuant to the DGCL.

THIRD: That Merger Sub shall merge with and into Parent, with Parent as the surviving entity of such Merger (the "Merger"), which Merger was authorized by the following resolutions of its Board of Directors adopted by written consent on March 20, 2023:

WHEREAS: The Corporation, is the legal and beneficial owner of 100% of the issued and outstanding shares of capital stock of Medtor, Inc., a Delaware corporation ("Medtor"); and

WHEREAS: The Board has determined it to be in the best interests of the Corporation and its Stockholders to merge Medtor with and into itself (the "Merger") pursuant to the provisions of Section 253 of the DGCL.

IN WITNESS WHEREOF, BE IT:

State of Delaware
Secretary of State
Division of Corporations
Delivered 02:34 PM 03/30/2023
FILED 02:34 PM 03/30/2023
SR 20231226672 - File Number 6898579


TRADEMARK
REEL: 008052 FRAME: 0044

- RESOLVED:** That, pursuant to Section 253 of the DGCL, Medtor shall be merged with and into the Corporation, such that the Corporation shall continue as the surviving corporation of such Merger and the separate corporate existence of Medtor shall cease.
- RESOLVED:** That the officers of the Corporation, in the name and on behalf of the Corporation be, and each hereby is authorized and directed to execute, deliver and cause a Certificate of Ownership and Merger (the “Certificate of Ownership”) to be filed with the Delaware Secretary of State, and to execute and deliver all such other documents, instruments and agreements and to take all such other actions necessary to consummate the Merger pursuant to and in accordance with applicable law.
- RESOLVED:** That the Merger shall become effective on March 31, 2023 (such time, the “Effective Time”);
- RESOLVED:** That, upon the Effective Time, all of the property, rights, privileges, powers and franchises of Medtor shall vest in the Corporation and all of the debts, liabilities and duties of Medtor shall become the debts, liabilities and duties of the Corporation.
- RESOLVED:** That the officers of the Corporation (and each of them acting singly) be, and each hereby is, authorized and directed, in the name and on behalf of the Corporation, to take such additional actions, make such filings with and give such notices to governmental authorities, and execute and deliver such additional agreements, certificates, documents and instruments as they may deem necessary or appropriate to implement the provisions of the foregoing resolutions, the execution and delivery of all such documents to be conclusive evidence that such is within the authority of these resolutions.
- RESOLVED:** That this written consent may be executed and delivered by facsimile or other electronic delivery.

[remainder of page is intentionally left blank]

IN WITNESS WHEREOF, BioIntelliSense, Inc. has caused this Certificate of Ownership to be signed by the undersigned officer, this 30th day of March, 2023.

BioIntelliSense, Inc.

DocuSigned by:

By: _____
483FF9E7BED1478
Name: James R. Mault, M.D
Title: Chief Executive Officer